01 December 2004
Can perinatal supplementation of long-chain polyunsaturated fatty acids prevents schizophrenia in adult life?
Undurti N. DasMed Sci Monit 2004; 10(12): HY33-37 :: ID: 13218
Abstract
It is suggested that perinatal supplementation of long-chain polyunsaturated fatty acids (LCPUFAs) especially; eicosapentaenoic and docosahexaenoic acids prevent schizophrenia in the adult. I propose that schizophrenia could be a low-grade systemic inflammatory disease with its origins in the perinatal period, probably triggered by maternal infection in a genetically susceptible individual that leads to excess production of pro-inflammatory cytokines both in the mother and the fetus. These cytokines, in turn, induce damage to the fetal neurons leading to the adult onset of schizophrenia. I suggest that maternal infection perse interferes with the metabolism of essential fatty acids (EFAs) resulting in deficiency of LCPUFAs that are known to have neuroprotective action. Alternatively, decreased formation of LCPUFAs as a result of decreased activity of D6 and D5 desaturases (due to prematurity) can result in neuronal damage due to the absence/decrease in the neuroprotective LCPUFAs. This is supported by the observation that LCPUFAs suppress the production of pro-inflammatory cytokines, have anti-inflammatory and neuroprotective actions. Furthermore, LCPUFAs are essential for brain growth and development. If this hypothesis is true, it implies that perinatal supplementation of appropriate amounts of LCPUFAs in the right combination is helpful in the prevention of schizophrenia in adult life.
Keywords: Dietary Fats, Unsaturated - therapeutic use, Docosahexaenoic Acids - administration & dosage, Eicosapentaenoic Acid - administration & dosage, Eicosapentaenoic Acid - therapeutic use, Fatty Acids, Essential - metabolism, Fatty Acids, Unsaturated - therapeutic use, Cytokines - metabolism, Dietary Fats, Unsaturated - therapeutic use, Dietary Supplements, Docosahexaenoic Acids - therapeutic use, Eicosapentaenoic Acid - therapeutic use, Fatty Acids, Essential - metabolism, Fatty Acids, Unsaturated - therapeutic use, Infection - immunology, Inflammation - immunology, Schizophrenia - prevention & control
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
18 Mar 2024 : Clinical Research
Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative StudyMed Sci Monit In Press; DOI: 10.12659/MSM.944136
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
Most Viewed Current Articles
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952